An interventional study of transcranial alternating current stimulation and sham stimulation in Schizophrenia and Working Memory, sponsored by Central South University. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Central South University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Schizophrenia by Central South University — 10 open to participants now, 10 under way, 1 of them phase 3. Schizophrenia · Central South University.
Among the 34 studies in Schizophrenia by Central South University, this one is the 26th largest by planned enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2026, is one of 18 with no phase, and was the 32nd registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →10 of the 34 studies in Schizophrenia by Central South University are open now, in 1 country. Recruiting first, the newest first:
Central South University · Sites in China
Ages 18–35
Central South University · Sites in China
Ages 18–50
Central South University · Sites in China
Ages 18–65
Central South University · Sites in China
Healthy volunteers
Central South University · Sites in China
Ages up to 60
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 80 across the 28 interventional studies, 207 across the 6 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Central South University is the lead sponsor of 136 studies on the registry; 32 are open to participants now.
3 of the studies in Schizophrenia by Central South University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06673966Central South UniversityImmunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia | 2027-02-01 |
| NCT07647380Central South UniversityTIS for Improving Cognitive Impairment in Schizophrenia | 2027-03-01 |
| NCT07927790Central South UniversityTemporal Interference Stimulation Targeting Thalamus for Schizophrenia-Related Cognitive Dysfunction | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 34 studies in Schizophrenia by Central South University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, single-blind, sham-controlled crossover trial enrolling 30 schizophrenia patients, each receiving one active and one sham tACS session (7-day washout), targeting P3/P4 at individual alpha frequency (2mA, 30min) during a working memory task, with accuracy and reaction time as primary outcomes, alongside EEG and neurophysiological measures, to test the efficacy and mechanisms of individualized alpha-tACS on working memory.
This study is a randomized, single-blind, sham-controlled, crossover exploratory trial that plans to enroll 30 inpatients with schizophrenia, randomized 1:1 into two groups, with all participants receiving one active and one sham tACS session in a crossover manner separated by a 7-day washout. Stimulation targets the parietal P3/P4 sites at individual alpha frequency, with an intensity of 2 mA and a duration of 30 minutes per session, delivered concurrently with a working memory task (SIRP). Primary outcomes are SIRP accuracy and reaction time, with concurrent task-state EEG recording, along with assessments of clinical symptoms, cognitive function, and neurophysiological markers including ASSR, MMN, and P300. The study aims to explore the efficacy and underlying neural mechanisms of individualized alpha-tACS in improving working memory in schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sham stimulation
Device: sham stimulation
transcranial alternating current stimulation
Device: transcranial alternating current stimulation
For montage 1, active electrode at P3 (10-10 system), return electrodes at P1, P5, PO3, CP3. For montage 2, active electrode at P4, return electrodes at P2, P6, PO4, CP4. Conductive paste ensures impedance \<10 kΩ. Individual alpha frequency is used, calculated before each session from mean EEG at P3/P4 during SIRP task. Stimulation intensity is 2 mA (peak-to-zero) via electric field modeling. Stimulation is delivered during SIRP task, 30 min total per session (including 15s ramp-up/down), with continuous sine wave output.
Sham stimulation provides only a 15-second ramp-up and ramp-down current at the beginning and end of each session to mimic the initial tingling or itching sensation on the scalp produced by real stimulation, but delivers no effective stimulation current during the main phase of the task period.
Working Memory Accuracy
Assessment of task accuracy on the Sternberg Item Recognition Paradigm (SIRP). Participants are required to judge whether a probe stimulus belongs to a previously memorized set. The outcome is measured as the percentage of correct responses (0-100%) across all trials, with higher scores indicating better working memory performance.
Time frame: Day 1 (baseline, before the first intervention, during the intervention, and within 15 minutes after the intervention); Day 9 (before the second intervention, during the intervention, and within 15 minutes after the intervention).
Working Memory Reaction Time
Assessment of response speed on the Sternberg Item Recognition Paradigm (SIRP). Participants are required to judge whether a probe stimulus belongs to a previously memorized set. The outcome is measured as the mean response latency for correct responses only, calculated from stimulus onset to the participant's button press, with shorter times indicating faster processing speed.
Time frame: Day 1 (baseline, before the first intervention, during the intervention, and within 15 minutes after the intervention); Day 9 (before the second intervention, during the intervention, and within 15 minutes after the intervention).
Changes in MCCB Performance
Assessment of cognitive function using the MATRICS Consensus Cognitive Battery (MCCB), a standardized cognitive assessment tool designed for schizophrenia and other neuropsychiatric conditions. The MCCB evaluates 9 cognitive domains: attention, information processing speed, verbal learning and memory, visual learning and memory, spatial working memory, reasoning and problem solving, social cognition, executive function, and fine motor skills. The overall cognitive composite score ranges from 20 to 100 (T-score), with higher scores indicating better cognitive performance.
Time frame: Baseline, on the day after each of the two interventions
Changes in Positive and Negative Symptom Scale (PANSS) Scores
Scores range from 30 to 210, with higher scores indicating more severe positive and negative symptoms.
Time frame: Before and one week after each of the two interventions.
Changes in Scale for the Assessment of Negative Symptoms (SANS) Scores
Scores range from 0 to 120; higher scores indicate more severe negative symptoms.
Time frame: Before and one week after each of the two interventions.
Changes in Calgary Depression Scale for Schizophrenia (CDSS) Scores
Scores range from 0 to 27; higher scores indicate more severe affective symptoms.
Time frame: Before and one week after each of the two interventions.
Changes in Brain Function
Functional magnetic resonance imaging (fMRI), based on blood oxygen level-dependent (BOLD) contrast, can detect changes in blood oxygenation and analyze changes in brain function after intervention.
Time frame: Baseline, on the day after each of the two interventions.
Changes in Neuroelectrophysiological Signals
Changes in neuroelectrophysiological signals are collected through task-based electroencephalography (EEG).
Time frame: Baseline, 30 minutes after each of the two interventions.
Changes in 40Hz Auditory Steady-State Response (40Hz-ASSR)
The 40Hz auditory steady-state response recorded by EEG, including evoked power and inter-trial phase coherence, will be measured. The unit of measurement for evoked power is μV², and for coherence is unitless.
Time frame: Baseline, 30 minutes after each of the two interventions.
Changes in Mismatch Negativity (MMN)
Mismatch negativity amplitude recorded by EEG using an oddball paradigm will be measured. The unit of measurement is microvolts (μV).
Time frame: Baseline, 30 minutes after each of the two interventions.
Changes in P300 Event-Related Potential
P300 amplitude recorded by EEG using an oddball paradigm will be measured. The unit of measurement is microvolts (μV).
Time frame: Baseline, 30 minutes after each of the two interventions.
Hallucination Visual Analog Scale
Assessment of acute post-intervention changes in hallucination severity using a patient-rated visual analog scale (VAS). The scale consists of a 0-100 mm horizontal line, on which participants mark their current symptom severity. The distance (in millimeters) from the left anchor ("no symptoms") to the participant's mark is measured with a ruler. This scale serves as a supplementary measure to the PANSS to capture immediate symptom changes following each intervention. Scores range from 0 to 100 mm, with higher scores indicating more severe hallucinations .
Time frame: Within 15 minutes before and after completion of Session 1; within 15 minutes before and after completion of Session 2.
Delusion Visual Analog Scale
Assessment of acute post-intervention changes in state paranoia severity using a patient-rated visual analog scale (VAS). The scale consists of a 0-100 mm horizontal line, on which participants mark their current symptom severity. The distance (in millimeters) from the left anchor ("no symptoms") to the participant's mark is measured with a ruler. This scale serves as a supplementary measure to the PANSS to capture immediate symptom changes following each intervention. Scores range from 0 to 100 mm, with higher scores indicating more severe state paranoia .
Time frame: Within 15 minutes before and after completion of Session 1; within 15 minutes before and after completion of Session 2.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2026, 0 months later.
Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 0 months is below that.
Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.